STROBE Statement—Checklist of items that should be included in reports of ***cross-sectional studies***

	Item No	Recommendation	Reported Section & Page	Status
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	Title & Abstract (Pages 1,3)	
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract (Page 3)	
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Introduction (Pages 4-5)	
Objectives	3	State specific objectives, including any prespecified hypotheses	Introduction (Page 5)	
Methods				
Study design	4	Present key elements of study design early in the paper	Methods (Page 18)	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Methods (Pages 18-19)	
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants	Methods (Pages 18-19)	V Consecutive sampling was used but the denominator was not recorded.
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Methods (Pages 19-21)	V
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Methods (Pages 19-21)	V
Bias	9	Describe any efforts to address potential sources of bias	Discussion (Pages 15-17)	V
Study size	10	Explain how the study size was arrived at	Discussion & Methods (Pages 17-18)	V
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Methods & Tables (Pages 21, 30)	V
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for	Methods (Page 21)	V

		confounding		
		(*b*) Describe any methods used to examine subgroups and interactions	Methods & Results (Pages 8, 21)	V
		(*c*) Explain how missing data were addressed	Methods (Pages 18-19)	V Complete-case analysis
		(*d*) If applicable, describe analytical methods taking account of sampling strategy		Not applicable
		(*e*) Describe any sensitivity analyses	Results & Discussion (Pages 16, 21)	
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Results (Page 5)	V The number of patients approached, declined, and excluded was not recorded
		(b) Give reasons for non-participation at each stage	Results & Discussion (Pages 5, 15-16)	Acknowledged
		(c) Consider use of a flow diagram	Results (Page 5)	V
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Results (Pages 5-6)	V Data on characteristics of non-respondents are unavailable (major limitation)
		(b) Indicate number of participants with missing data for each variable of interest	Results (Pages 5-6)	V
Outcome data	15*	Report numbers of outcome events or summary measures	Results (Pages 5-6)	V
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Results (Pages 6-9)	V
		(*b*) Report category boundaries when continuous variables were categorized	Results (Pages 8-9)	V
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period		Not applicable
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and	Results & Discussion	V

		sensitivity analyses	(Pages 8-9, 16, 21)	
Discussion				
Key results	18	Summarise key results with reference to study objectives	Discussion (Pages 9-10)	V
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Discussion (Pages 15-17)	V
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Discussion (Pages 12-17)	V
Generalisability	21	Discuss the generalisability (external validity) of the study results	Discussion (Pages 15-17)	V
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 24	V

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.